Development of binary dispersions and nanocomposites of irbesartan with enhanced antihypertensive activity.

Conclusion: Nanocomposites proved superior carriers to solid dispersions in terms of the dissolution enhancement. Further, in vivo studies indicated that the induction of systolic and diastolic blood pressure in the optimized formulation (NC1) was significantly decreased in comparison to the disease control group (P <0.01) at all time intervals along with pure drug (P <0.05). PMID: 32983943 [PubMed]
Source: BioImpacts - Category: Research Tags: Bioimpacts Source Type: research